{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:28:00Z","timestamp":1792211280473,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejrad.2025.112056","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:42:23Z","timestamp":1742492543000},"page":"112056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection"],"prefix":"10.1016","volume":"187","author":[{"given":"Tetiana","family":"Glushko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Chima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McGettigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejrad.2025.112056_b0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"7","key":"10.1016\/j.ejrad.2025.112056_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"issue":"23","key":"10.1016\/j.ejrad.2025.112056_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233929","article-title":"FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells."},{"issue":"9","key":"10.1016\/j.ejrad.2025.112056_b0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejrad.2025.112056_b0025","article-title":"Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma","volume":"9","author":"Chung","year":"2022","journal-title":"Front Med (lausanne)."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000521747","article-title":"Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value","volume":"11","author":"Park","year":"2022","journal-title":"Liver Cancer."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40644-023-00533-2","article-title":"Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma","volume":"23","author":"Xiao","year":"2023","journal-title":"Cancer Imaging"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112056_b0040","doi-asserted-by":"crossref","first-page":"W64","DOI":"10.2214\/AJR.16.16923","article-title":"Cross-Sectional Imaging of Intrahepatic Cholangiocarcinoma: Development, Growth, Spread, and Prognosis","volume":"209","author":"Seo","year":"2017","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.ejrad.2025.112056_b0045","article-title":"Spectrum of Findings Seen in Patients With IDH1\/2-Mutant Cholangiocarcinoma","volume":"10668969241271397","author":"Kierans","year":"2024","journal-title":"Int J Surg Pathol."},{"key":"10.1016\/j.ejrad.2025.112056_b0050","doi-asserted-by":"crossref","unstructured":"van Keulen AM, Buttner S, Erdmann JI, Hagendoorn J, Hoogwater FJH, JNM IJ, et al. Major complications and mortality after resection of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Surgery. 2023;173(4):973-82.","DOI":"10.1016\/j.surg.2022.11.027"},{"key":"10.1016\/j.ejrad.2025.112056_b0055","article-title":"Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection","author":"Choi","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejrad.2025.112056_b0060","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ejrad.2025.112056_b0065","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ejrad.2025.112056_b0070","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.ejrad.2025.112056_b0075","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.3748\/wjg.v20.i30.10316","article-title":"FOLFOX\/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy","volume":"20","author":"Mohelnikova-Duchonova","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.ejrad.2025.112056_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejrad.2025.112056_b0085","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1(8):EVIDoa2200015","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"10391","key":"10.1016\/j.ejrad.2025.112056_b0090","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2025.112056_b0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br J Cancer."},{"key":"10.1016\/j.ejrad.2025.112056_b0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients","volume":"4","author":"Cao","year":"2020","journal-title":"Jco Precis Oncol."},{"key":"10.1016\/j.ejrad.2025.112056_b0110","doi-asserted-by":"crossref","unstructured":"Uson PJr, Araujo RLC. Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World J Gastro Oncol. 2022;14(8):1446-55.","DOI":"10.4251\/wjgo.v14.i8.1446"},{"key":"10.1016\/j.ejrad.2025.112056_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030688","article-title":"New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.ejrad.2025.112056_b0125","article-title":"Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0130","doi-asserted-by":"crossref","first-page":"18775","DOI":"10.1038\/s41598-022-22543-z","article-title":"Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma","volume":"12","author":"Rimini","year":"2022","journal-title":"Sci Rep."},{"issue":"7516","key":"10.1016\/j.ejrad.2025.112056_b0135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejrad.2025.112056_b0140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist."},{"issue":"10","key":"10.1016\/j.ejrad.2025.112056_b0145","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol."},{"issue":"13","key":"10.1016\/j.ejrad.2025.112056_b0150","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112056_b0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ejrad.2025.112056_b0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol."},{"key":"10.1016\/j.ejrad.2025.112056_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"Jco Precis Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0180","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"11","key":"10.1016\/j.ejrad.2025.112056_b0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg."},{"issue":"16","key":"10.1016\/j.ejrad.2025.112056_b0195","article-title":"Characterizing allele variants within biliary tract cancers","volume":"41","author":"Moffat","year":"2023","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0200","article-title":"Comprehensive pan-cancer genomic landscape of altered cancers and real-world outcomes in solid tumors. Npj Precision","volume":"6","author":"Lee","year":"2022","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.ejrad.2025.112056_b0205","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/liv.15366","article-title":"mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression","volume":"42","author":"Tanaka","year":"2022","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12072-022-10445-1","article-title":"The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion","volume":"17","author":"Meng","year":"2023","journal-title":"Hepatol Int."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112056_b0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tranon.2018.10.007","article-title":"Attenuation of CD47-SIRP\u03b1 Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis","volume":"12","author":"Vaeteewoottacharn","year":"2019","journal-title":"Transl Oncol."},{"key":"10.1016\/j.ejrad.2025.112056_b0225","article-title":"Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials","volume":"7","author":"Karasic","year":"2023","journal-title":"Jco Precis Oncol."},{"issue":"5","key":"10.1016\/j.ejrad.2025.112056_b0230","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","article-title":"Universal Patterns of Selection in Cancer and Somatic Tissues","volume":"171","author":"Martincorena","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0235","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics."},{"issue":"12","key":"10.1016\/j.ejrad.2025.112056_b0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9 - tumor marker: Past, present, and future","volume":"12","author":"Lee","year":"2020","journal-title":"World J Gastrointest Surg."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112056_b0245","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1515\/CCLM.2009.152","article-title":"Increased CA 19-9 level in patients without malignant disease","volume":"47","author":"Kim","year":"2009","journal-title":"Clin Chem Lab Med."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112056_b0250","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2005.03.040","volume":"128","author":"Lazaridis","year":"2005","journal-title":"Cholangiocarcinoma. Gastroenterology."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0255","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in Cell Death and Human Cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejrad.2025.112056_b0260","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer."},{"key":"10.1016\/j.ejrad.2025.112056_b0265","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ejrad.2025.112056_b0270","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in , and in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0275","article-title":"Genetic alterations of and in intrahepatic cholangiocarcinoma associated with poor prognosis. Open","volume":"18","author":"Peng","year":"2023","journal-title":"Life Sci."},{"issue":"3\u20134","key":"10.1016\/j.ejrad.2025.112056_b0280","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1947601912455199","article-title":"Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity","volume":"3","author":"Shi","year":"2012","journal-title":"Genes Cancer."},{"key":"10.1016\/j.ejrad.2025.112056_b0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/OTT.S440979","article-title":"Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series","volume":"17","author":"Yamamoto","year":"2024","journal-title":"Onco Targets Ther."},{"issue":"16","key":"10.1016\/j.ejrad.2025.112056_b0290","article-title":"A phase 2 study of the MDM2 inhibitor milademetan in patients with 53-wild type and 2-amplified advanced or metastatic solid tumors (MANTRA-2)","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.ejrad.2025.112056_b0295","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist."},{"issue":"15","key":"10.1016\/j.ejrad.2025.112056_b0300","article-title":"Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI)","volume":"37","author":"Spizzo","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0305","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"issue":"46","key":"10.1016\/j.ejrad.2025.112056_b0310","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.3748\/wjg.v22.i46.10254","article-title":"Response of BRCA1-mutated gallbladder cancer to olaparib: A case report","volume":"22","author":"Xie","year":"2016","journal-title":"World J Gastroenterol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112056_b0315","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","article-title":"Roles and mechanisms of BAP1 deubiquitinase in tumor suppression","volume":"28","author":"Masclef","year":"2021","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112056_b0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","article-title":"Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma","volume":"30","author":"Masoomian","year":"2018","journal-title":"J Curr Ophthalmol."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112056_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081247","article-title":"Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis","volume":"12","author":"Rizzo","year":"2022","journal-title":"J Pers Med."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0330","article-title":"BAP1 mutation-associated cholangiocarcinoma: An aggressive disease","volume":"33","author":"Anand","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112056_b0335","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/ajcp\/aqw071","article-title":"Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas","volume":"145","author":"Sasaki","year":"2016","journal-title":"Am J Clin Pathol."},{"issue":"25","key":"10.1016\/j.ejrad.2025.112056_b0340","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.3748\/wjg.v22.i25.5814","article-title":"Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroentero."},{"key":"10.1016\/j.ejrad.2025.112056_b0345","article-title":"High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study. Bmc","volume":"19","author":"Bi","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejrad.2025.112056_b0350","article-title":"BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective","volume":"12","author":"Yan","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0355","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820983013","article-title":"Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges","volume":"27","author":"Rizzo","year":"2020","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0360","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1476","article-title":"Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma","volume":"6","author":"Xin","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112056_b0365","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ejrad.2025.112056_b0370","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0375","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5644\/ama2006-124.392","article-title":"Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group","volume":"51","author":"Vranic","year":"2022","journal-title":"Acta Med Acad."},{"key":"10.1016\/j.ejrad.2025.112056_b0380","article-title":"A comprehensive overview of the relationship between RET gene and tumor occurrence","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0385","article-title":"Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting","volume":"8","author":"Hackshaw","year":"2024","journal-title":"Jco Precis Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112056_b0390","article-title":"Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with fusion-positive solid tumors","volume":"39","author":"Subbiah","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejrad.2025.112056_b0395","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int."},{"issue":"4","key":"10.1016\/j.ejrad.2025.112056_b0400","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"issue":"24","key":"10.1016\/j.ejrad.2025.112056_b0405","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejrad.2025.112056_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113564","article-title":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives","volume":"199","author":"Ten Haaft","year":"2024","journal-title":"Eur J Cancer."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112056_b0415","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.ejrad.2025.112056_b0420","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncologist."},{"issue":"9","key":"10.1016\/j.ejrad.2025.112056_b0425","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2025.112056_b0430","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30(Suppl_8):viii5-viii15","author":"Amatu","year":"2019","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.ejrad.2025.112056_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042366","article-title":"NTRK Therapy among Different Types of Cancers, Review and Future Perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112056_b0440","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ejrad.2025.112056_b0445","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/oncolo\/oyac139","article-title":"An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma","volume":"27","author":"Madoff","year":"2022","journal-title":"Oncologist."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T10:35:52Z","timestamp":1753785352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":89,"alternative-id":["S0720048X25001421"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112056","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112056"}}